PubRank

George C Prendergast

Author PubWeight™ 87.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005 4.92
2 Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007 3.44
3 Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007 2.78
4 IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012 2.56
5 Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008 2.47
6 Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008 2.18
7 RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell 2004 2.13
8 Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007 1.86
9 Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis 2011 1.86
10 Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006 1.81
11 RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev 2003 1.48
12 Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther 2003 1.46
13 Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci 2012 1.40
14 IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 2012 1.37
15 Cyclin D1 functions in cell migration. Cell Cycle 2006 1.36
16 The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry 2006 1.35
17 The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009 1.34
18 Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol 2003 1.26
19 Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem 2008 1.25
20 Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 2010 1.22
21 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008 1.18
22 Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002 1.18
23 Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev 2012 1.16
24 Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009 1.11
25 Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 2007 1.10
26 Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008 1.07
27 Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 2010 1.06
28 Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 2010 1.04
29 Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 2005 1.04
30 Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005 1.02
31 RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2007 1.02
32 Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res 2012 1.01
33 Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res 2003 1.00
34 Cancer: Why tumours eat tryptophan. Nature 2011 0.99
35 Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res 2011 0.97
36 Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochem Biophys Res Commun 2005 0.96
37 Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene 2003 0.96
38 AACR Cancer Progress Report 2013. Clin Cancer Res 2013 0.95
39 Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther 2010 0.94
40 A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci 2010 0.93
41 Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res 2008 0.93
42 Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy 2010 0.91
43 RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem 2011 0.90
44 The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol 2014 0.89
45 Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther 2011 0.89
46 Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 2002 0.89
47 Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem 2003 0.89
48 Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 2007 0.89
49 CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. J Radiat Oncol 2013 0.88
50 Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther 2007 0.86
51 RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res 2012 0.85
52 RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun 2013 0.84
53 Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicol In Vitro 2012 0.84
54 Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res 2004 0.83
55 hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene 2003 0.83
56 Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biol Ther 2005 0.82
57 The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Dev Biol 2013 0.82
58 Genomic profiling of miRNAs in two human lens cell lines. Curr Eye Res 2010 0.82
59 Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene 2003 0.82
60 Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther 2004 0.81
61 Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One 2009 0.81
62 mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther 2007 0.80
63 Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol 2009 0.79
64 Altered apoptotic responses in neurons lacking RhoB GTPase. Eur J Neurosci 2011 0.79
65 A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicol In Vitro 2012 0.79
66 RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol 2010 0.79
67 Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle 2007 0.78
68 RIN3 is a negative regulator of mast cell responses to SCF. PLoS One 2012 0.78
69 Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther 2011 0.78
70 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity 2014 0.77
71 Specific in situ detection of murine indoleamine 2, 3-dioxygenase. J Cell Biochem 2014 0.76
72 Perspectives on emerging trends in cancer research. Cancer Res 2011 0.76
73 Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle 2007 0.75
74 In their own words: interviews with Cell Cycle. Cell Cycle 2010 0.75
75 A perspective on cancer as an abortive autoimmune response to altered-self. Cancer Res 2015 0.75
76 Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal. Cancer Res 2016 0.75
77 Development of a monoclonal antibody that specifically detects tissue inhibitor of metalloproteinase-4 (TIMP-4) in formalin-fixed, paraffin-embedded human tissues. J Cell Biochem 2010 0.75